Abstract
Phenomycin, a new polypeptide antibiotic, was observed to exhibit significant inhibitory activity against Ehrlich carcinoma and sarcoma 180 in ddD mice, both ascitic and subcutaneous solid forms. It also showed a marked activity against the growth of adenocarcinoma 755 in C57BL/6 mice. The LD50 for mice was 8 mg/kg both by intraperitoneal and subcutaneous injections.
